Journal
CURRENT COLORECTAL CANCER REPORTS
Volume 12, Issue 1, Pages 27-34Publisher
SPRINGER
DOI: 10.1007/s11888-016-0306-9
Keywords
Aspirin; Acetylsalicylic acid; NSAID; Colorectal cancer; Chemoprevention; Secondary prevention; Primary prevention; Adjuvant therapy; Bleeding; PIK3CA; BRAF; Single-nucleotide polymorphism; Human leukocyte antigen
Categories
Funding
- MRC [MC_UU_12023/28] Funding Source: UKRI
- Cancer Research UK [15015] Funding Source: researchfish
- Medical Research Council [MC_UU_12023/28, 1549995] Funding Source: researchfish
- National Institute for Health Research [12/01/38] Funding Source: researchfish
Ask authors/readers for more resources
There is now a considerable body of data supporting the hypothesis that aspirin could be effective in the prevention and treatment of colorectal cancer, and a number of phase III randomised controlled trials designed to evaluate the role of aspirin in the treatment of colorectal cancer are ongoing. Although generally well tolerated, aspirin can have adverse effects, including dyspepsia and, infrequently, bleeding. To ensure a favourable balance of benefits and risks from aspirin, a more personalised assessment of the advantages and disadvantages is required. Emerging data suggest that tumour PIK3CA mutation status, expression of cyclo-oxygenase-2 and human leukocyte antigen class I, along with certain germline polymorphisms, might all help to identify individuals who stand to gain most. We review both the underpinning evidence and current data, on clinical, molecular and genetic biomarkers for aspirin use in the prevention and treatment of colorectal cancer, and discuss the opportunities for further biomarker research provided by ongoing trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available